> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Qulipta Approval Used Priority Voucher
- URL: https://www.fdaweb.com/qulipta-approval-used-priority-voucher/
- Published: 2024-01-22T12:00:00.000Z
- Updated: 2026-09-14T14:20:48.000Z
- Author: David McFarland
- Tags: FDA Policy/General, #legacy-id-D5156186

*Federal Register* notice: FDA is announcing that a product was approved that redeemed a material threat medical countermeasure priority review voucher — Abbvie’s Qulipta (atogepant) tablets, indicated for preventing migraines in adults. To view the notice, click [here](https://www.govinfo.gov/content/pkg/FR-2024-01-22/pdf/2024-01108.pdf?ref=fdaweb.com).